Friends! In this video, I'm going to talk about the best quality stocks to consider
2 extracted signals · 2 resolved · 0 still active
The Patient Investor10 Sept 2025, 22:14 UTC
AI-generated source summary
This is a fundamental analysis of two stock CPRT and UBER. The first stock, Copart, is currently priced at $48.07, down -14.65% year to date. He states he is looking for a target price of $59 and owns call options going into 2027. He explains that Copart makes revenue in two ways, service revenue which is currently up 7.1% and vehicle sales. Next is UBER, which is showing a strong YTD returns, this is a very disliked stock. Price of the stock is $94.36 with a target price of around $110, for a stock that the market underappreciates. Uber's moat and also annual earnings per share growth, of 30% or greater. Analyst are showing that earnings will continue to grow as this will impact the share price. Looking at delivery segment gross bookings are up 20% in 2025.
AI-generated summary based on the source content.
Evidence and evaluation progress
- Original source published
The analyst published the original source item.
- First prediction resolved
The first evaluable outcome in this case reached a terminal result.
- Case evaluation completed
All evaluable predictions in this case reached terminal outcomes.
- Source recorded by Tahlil Plus
The public source was preserved as the evidence record for this case.
- Market predictions extracted
2 eligible signals linked to this case.
- Outcome tracking started
Tahlil Plus began monitoring the extracted predictions.
Signals in this source
More Prediction Case Files from The Patient Investor
Why I Don't Own Google Stock & When I'm Buying
The CHEAPEST Quality Stock In The Stock Market!
Intuitive Surgical Stock Analysis! Risks & Upside Potential
There Is NO AI BUBBLE! I’m Buying Every Dip
2 Stocks I'm Buying In The Next 2 Weeks
Netflix Stock Is FINALLY A Buy!
The Patient Investor
Tahlil Plus independently records and evaluates public market predictions. Extraction may be AI-assisted and results follow the Tahlil Plus methodology. This information is not financial advice.

